Cardio Diagnostics Holdings
Open
$1.81
Prev. Close
$1.81
High
$1.81
Low
$1.79
Market Snapshot
$3.1M
-0.5
-3.92
$19.9K
16
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
emptyResult
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Recently from Cashu
Cardio Diagnostics Holdings (CDIO) Expands Partnerships in Precision Cardiovascular Medicine for Enhanced Care
Cardio Diagnostics Expands Reach Through Strategic Partnerships in Precision Cardiovascular Medicine Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in AI-driven Precision Cardiovascular Me…
Cardio Diagnostics Holdings Expands Partnerships to Enhance Precision Cardiovascular Care
Cardio Diagnostics Expands Reach with New Healthcare Partnerships Cardio Diagnostics Holdings, Inc., a leader in AI-driven Precision Cardiovascular Medicine, announces a significant expansion through…
Cardio Diagnostics Holdings Receives CMS Approval for Groundbreaking Cardiovascular Tests
Cardio Diagnostics Secures CMS Approval for Innovative Cardiovascular Tests Cardio Diagnostics Holdings, Inc. announces a significant advancement in its operations with the final pricing determination…
Cardio Diagnostics Secures CMS Pricing for PrecisionCHD and Epi+Gen CHD Tests
Cardio Diagnostics Advances Cardiovascular Care with CMS Pricing Determination Cardio Diagnostics Holdings, Inc., a pioneering company in AI-driven precision cardiovascular medicine, celebrates a sign…